HRT and Clotting Disorders: What Every Woman Needs to Know Before Starting Hormone Therapy

Why HRT and Blood Clotting Are Linked

Estrogen raises hepatic synthesis of several coagulation factors, including fibrinogen, factor VIII, and factor X, while also suppressing natural anticoagulants such as protein S. Oral estrogen is absorbed through the gut and passes directly to the liver in high concentrations, a phenomenon called first-pass hepatic metabolism. That liver exposure amplifies procoagulant changes far more than skin-absorbed estrogen does.

The Women's Health Initiative (WHI) oral conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) trial, which enrolled 16,608 postmenopausal women aged 50, 79, found a hazard ratio of 2.06 (95% CI: 1.57, 2.70) for VTE compared with placebo over a mean follow-up of 5.2 years [1]. The estrogen-only arm (CEE alone, N=10,739) showed a hazard ratio of 1.32 (95% CI: 0.99, 1.75), suggesting the MPA component added independent risk [2]. These findings drove two decades of caution, but they were derived almost exclusively from one oral formulation and one synthetic progestogen.

The picture changes substantially with different delivery methods. The ESTHER (Estrogen and Thromboembolism Risk) case-control study, published in Circulation in 2003 and involving 271 VTE cases and 610 controls, found an odds ratio of 4.2 (95% CI: 1.5, 11.6) for oral estrogen versus no HRT, but an odds ratio of 0.9 (95% CI: 0.4, 2.1) for transdermal estradiol, meaning no significant elevation above baseline [3]. That single finding reshaped prescribing practice across Europe and is now embedded in multiple national guidelines.

Transdermal vs. Oral Estrogen: The Route Matters More Than the Hormone

Transdermal estradiol delivers 17-beta-estradiol directly into the bloodstream, bypassing the liver entirely. This means hepatic coagulation factor synthesis stays close to pre-treatment levels. Evidence consistently supports a lower clotting burden with the patch, gel, or spray compared with any oral formulation.

A 2010 meta-analysis published in the BMJ, pooling data from 12 studies, found that oral HRT was associated with an approximately 2-fold higher VTE risk (OR 2.08 to 95% CI: 1.83, 2.37), while transdermal HRT showed no significant excess risk (OR 0.96 to 95% CI: 0.70, 1.31) [4]. A low dose patch (estradiol 25 to 50 mcg/day) or a gel supplying approximately 0.75 to 1.5 mg estradiol per day are the clinically preferred starting points for any woman with a personal or family history of clotting.

Practically speaking: if a woman has used oral estrogen for years without incident and wishes to continue, her absolute residual risk may still be low depending on her baseline. Switching her to a patch is not an emergency. It is, however, the better choice for anyone starting fresh who has any VTE risk factor on her record.

Progestogen Choice Adds a Second Layer of Risk

Women with an intact uterus must take a progestogen alongside estrogen to protect the endometrium. Not all progestogens carry the same clotting profile. Synthetic progestins, particularly medroxyprogesterone acetate (Provera, Depo-Provera) and norethindrone acetate, appear to add independent VTE risk on top of estrogen [5].

Micronized progesterone (sold as Prometrium in the United States and Utrogestan in the UK) is bioidentical to the progesterone the body produces. The ESTHER study found that women using transdermal estradiol plus micronized progesterone had no statistically significant VTE excess compared with non-users [3]. A 2011 French cohort study (the E3N study, N=80,377 postmenopausal women) confirmed that the combination of transdermal estradiol with micronized progesterone carried the lowest VTE hazard ratio among all HRT regimens studied, at 0.7 (95% CI: 0.4, 1.3) [5].

The 2022 Menopause Society (formerly NAMS) position statement notes: "Transdermal estrogen with micronized progesterone appears to have a more favorable VTE profile compared with oral estrogen-progestogen combinations." [6]

For women who cannot tolerate micronized progesterone (rare cases of peanut allergy, since Prometrium uses a peanut-oil base, or intolerance to the sedative side-effect), the lowest-risk synthetic alternative with available data is dydrogesterone, widely available in Europe though not FDA-approved in the United States.

Inherited and Acquired Thrombophilias: Who Needs Screening?

Thrombophilia is not a single condition. It includes inherited defects (Factor V Leiden, prothrombin gene mutation G20210A, protein C deficiency, protein S deficiency, antithrombin III deficiency) and acquired states (antiphospholipid antibody syndrome, or APS).

Factor V Leiden is the most common inherited thrombophilia in populations of European ancestry, present in approximately 5% of that group [7]. Heterozygous Factor V Leiden raises baseline annual VTE risk to about 0.5 to 0.7% per year compared with 0.1% for the general population. Oral estrogen in the setting of heterozygous Factor V Leiden has been estimated to increase VTE risk 15-fold above the general population baseline, though transdermal estrogen appears to carry far lower additive risk in this group [8].

Antiphospholipid syndrome with a prior thrombotic event is an absolute contraindication to any systemic estrogen, oral or transdermal, per British Menopause Society guidance [9]. Triple-positive APS (positive lupus anticoagulant, anticardiolipin, and anti-beta-2 glycoprotein antibodies) represents the highest-risk variant.

Routine thrombophilia screening before every HRT prescription is not recommended by most guidelines. The U.S. Preventive Services Task Force does not endorse universal screening [10]. Selective screening is warranted when a woman has a personal history of unprovoked DVT or PE, a first-degree relative with unprovoked VTE before age 50, or a known family history of a high-penetrance thrombophilia such as antithrombin III deficiency.

A practical screening panel for such women should include Factor V Leiden PCR, prothrombin G20210A mutation, protein C activity, protein S free antigen, antithrombin III activity, plus antiphospholipid antibody testing (lupus anticoagulant, anticardiolipin IgG/IgM, anti-beta-2 glycoprotein-1 IgG/IgM). Results should guide, not automatically exclude, HRT use. A hematologist consultation is appropriate before prescribing for any high-penetrance defect.

HRT During Perimenopause and Clotting Risk

Perimenopause typically spans the 4 to 10 years before the final menstrual period, with median onset in the mid-to-late 40s. Erratic estrogen surges and drops during this window drive vasomotor symptoms, mood changes, sleep disruption, and irregular bleeding. Many women in this phase are in their 40s, when baseline VTE risk is lower than it is at age 60 or 70.

The absolute VTE risk of oral HRT in a 45-year-old perimenopausal woman with no risk factors is low in absolute terms, but relative risk elevation still applies. Transdermal estradiol remains preferable for any woman with a clotting risk factor, including obesity (BMI above 30 kg/m2, a recognized independent VTE risk factor), smoking, immobility, or family history.

Women with irregular cycles in perimenopause who still have a uterus typically need a progestogen. Continuous-combined regimens (daily estrogen plus daily micronized progesterone) or sequential regimens (progesterone for 12 to 14 days per month) are both used. For women with heavy perimenopausal bleeding and a normal uterine cavity, a 52-mg levonorgestrel IUD (Mirena) provides excellent endometrial protection locally while systemic transdermal estradiol handles vasomotor symptoms, an approach endorsed in the 2023 British Menopause Society guidelines [9].

A useful clinical decision framework at HealthRX for perimenopausal women with documented or suspected clotting risk:

1. Confirm thrombophilia status if any red-flag history is present (see screening criteria above).
2. Start transdermal estradiol 0.0375 to 0.05 mg/day (patch) or equivalent gel dose.
3. Add micronized progesterone 100 mg nightly (continuous) or 200 mg nightly for 12 days per cycle (sequential) if uterus is intact.
4. Avoid oral estrogens and synthetic progestins in any woman with prior VTE, known thrombophilia, BMI above 35, or concurrent anticoagulation unless the prescribing physician has documented a specific rationale.
5. Reassess clotting risk at each annual review, particularly if the woman starts a long-haul flight schedule, undergoes elective surgery, or develops significant immobility.

HRT After Hysterectomy: Simplified and Lower Risk

Women who have had a hysterectomy (removal of the uterus) do not require a progestogen. Estrogen-only therapy removes the second layer of clotting concern introduced by synthetic progestins.

The WHI estrogen-only trial (CEE 0.625 mg oral daily, N=10,739) showed a non-significant VTE hazard ratio of 1.32, notably lower than the combination arm [2]. Transdermal estradiol alone in this group carries no measurable excess VTE risk in the available literature.

Post-hysterectomy women should still be assessed for personal VTE history, thrombophilia, and cardiovascular risk before prescription. For a woman in her early 50s with no additional risk factors who had a hysterectomy for fibroids, transdermal estradiol 0.05 mg/day is a straightforward and well-tolerated starting point. Dose titration upward (to 0.075 or 0.1 mg/day) is possible if symptom control is inadequate, though doses above 100 mcg/day have less safety data and move outside the ESTHER "no excess risk" threshold. Dose adjustments should be made in 0.025 mg increments at 6 to 8 week intervals.

Women who had a hysterectomy with bilateral oophorectomy (surgical menopause) before age 45 face a different calculus. Early loss of ovarian estrogen is associated with accelerated cardiovascular disease and osteoporosis. The Cochrane Review on premature ovarian insufficiency (2017) concluded that estrogen replacement in women with surgical menopause before age 45 reduced all-cause mortality risk and should be considered standard of care absent specific contraindication [11].

HRT in Late Postmenopausal Women: The Timing Hypothesis

The "timing hypothesis" (also called the "window of opportunity" or "healthy cell hypothesis") proposes that estrogen initiated within 10 years of menopause or before age 60 has a more favorable cardiovascular and cognitive risk profile than estrogen started later. The KRONOS Early Estrogen Prevention Study (KEEPS, N=727), a randomized trial of women within 3 years of their final menstrual period, found no increase in carotid intima-media thickness progression versus placebo after 4 years of treatment [12].

By contrast, initiating oral HRT more than 10 to 15 years after menopause in women with established arterial disease or advanced atherosclerosis may increase cardiovascular event rates, as suggested by subgroup analyses from WHI [1]. VTE risk follows a related pattern: older women starting oral HRT carry a higher absolute risk simply because their baseline age-related VTE incidence is higher.

For a woman in her late 60s requesting HRT primarily for genitourinary syndrome of menopause (GSM), low-dose vaginal estradiol (10 mcg vaginal tablet or 4 mcg/day vaginal ring, or topical vaginal estriol 0.1% cream applied twice weekly) achieves local tissue benefit with minimal systemic absorption and no clinically meaningful change in coagulation markers [13]. This approach sidesteps the VTE question for most women.

Systemic transdermal HRT started after age 60 for persistent moderate-to-severe vasomotor symptoms remains an option, but the 2022 Menopause Society guidelines state: "For women who initiate hormone therapy more than 10 years from menopause onset or who are older than 60 years, the benefit-risk ratio appears less favorable, primarily due to increased risks of coronary heart disease, stroke, VTE, and dementia." [6] Shared decision-making, documented in the chart, is non-negotiable for this group.

Managing HRT in Women Already on Anticoagulation

Women taking therapeutic anticoagulation (warfarin, rivaroxaban, apixaban, dabigatran) for a prior VTE or atrial fibrillation represent a distinct clinical category. Active therapeutic anticoagulation theoretically mitigates the procoagulant effect of HRT, but no large randomized trial has specifically studied HRT safety in fully anticoagulated postmenopausal women.

The British Menopause Society 2020 guidance notes that "transdermal HRT may be considered in women on established anticoagulation therapy after specialist review, as the systemic route avoids additional hepatic procoagulant stimulation." [9] The decision requires collaboration between the prescribing HRT clinician and the treating hematologist or anticoagulation specialist.

Practical points for this subset:

• Use transdermal estradiol only; no oral estrogen.
• Add micronized progesterone if uterus is present; avoid synthetic progestins.
• Confirm INR stability (if on warfarin) before initiating, since estrogen can modestly affect warfarin metabolism.
• Document duration of anticoagulation and whether the underlying VTE was provoked or unprovoked, as this affects the risk calculus for HRT indefinitely.

HRT With an Intact Uterus: Endometrial and Clotting Considerations Together

A woman with an intact uterus who also has a clotting risk factor faces the combined challenge of needing a progestogen (to prevent endometrial hyperplasia and cancer) while also wanting the lowest-risk progestogen formulation.

As noted in the E3N cohort, transdermal estradiol combined with micronized progesterone produces the lowest observed VTE signal among all progestogen-containing regimens [5]. The American College of Obstetricians and Gynecologists (ACOG) 2022 practice bulletin on menopausal hormone therapy states: "Micronized progesterone is associated with fewer metabolic and cardiovascular side effects compared with synthetic progestins based on available observational evidence." [14]

Endometrial safety requires at least 10 to 14 days of progestogen exposure per cycle in sequential regimens, or continuous daily dosing. Continuous combined micronized progesterone 100 mg nightly is an accepted regimen for postmenopausal women. Sequential regimens using 200 mg nightly for 12 days per month are typical for perimenopausal women who still want a monthly withdrawal bleed.

Irregular uterine bleeding on HRT always warrants investigation. A transvaginal ultrasound measuring endometrial thickness, with biopsy if thickness exceeds 4 mm in a postmenopausal woman on HRT, is the standard evaluation pathway per ACOG guidance [14].

Absolute and Relative Contraindications Summary

Absolute contraindications to any systemic HRT:

• Active or recent (within 3 to 6 months) VTE (DVT or pulmonary embolism)
• Active antiphospholipid syndrome with prior thrombosis
• Known antithrombin III deficiency (pending hematology evaluation and anticoagulation plan)
• Unexplained abnormal vaginal bleeding not yet evaluated

Relative contraindications requiring specialist input before prescribing:

• Personal history of provoked VTE more than 6 months ago, currently not anticoagulated
• Heterozygous Factor V Leiden or prothrombin G20210A mutation with no personal VTE history (transdermal route is strongly preferred)
• BMI above 40 kg/m2
• Major surgical procedure within 4 weeks or planned within 4 weeks
• Prolonged immobility (hospitalization, long-haul travel lasting more than 8 hours)

These categories come from the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) adapted categories and the British Menopause Society standing guidelines, cross-referenced against Menopause Society 2022 positions [6, 9].

Monitoring Women on HRT With Clotting Risk Factors

Annual review is the minimum standard. Each visit should include:

• Blood pressure measurement (hypertension adds independent VTE and stroke risk)
• BMI reassessment
• Review of any intercurrent thrombotic events, hospitalizations, or new diagnoses
• Discussion of any new family history of VTE that has come to light
• Confirmation that progestogen regimen is adequately protecting the endometrium
• Consideration of dose adjustment based on symptom control and tolerability

Routine repeat coagulation panels (PT, aPTT, d-dimer) are not indicated for asymptomatic women on stable transdermal HRT. Thrombophilia re-testing is only relevant if a new thrombotic event occurs or if pregnancy is being considered (in younger perimenopausal women).

The Menopause Society notes that "duration of hormone therapy should be based on the woman's individual goals, her health risks, and her preference for symptom management, with no arbitrary time limit imposed if benefits continue to outweigh risks." [6] For most women on transdermal estradiol plus micronized progesterone with no active thrombotic risk factor, annual review with shared decision-making on continuation is appropriate rather than a preset stop date.